
FDA Approves First-Ever Cholesterol-Lowering Pill Targeting PCSK9 for High-Risk Patients
July 20, 2026
The U.S. Food and Drug Administration (FDA) has approved Lipfendra, a groundbreaking oral medication developed by Merck, marking the first pill designed to lower cholesterol by targeting the PCSK9 protein. Until now, this treatment approach was available only through injectable









